AstraZeneca is set to expand its reach in lung cancer treatment with new clinical data presented at the ASCO meeting. The study showed that the drug Tagrisso improved progression-free survival in patients with EGFR-mutated NSCLC. Another drug, Imfinzi, in combination with tremelimumab, also showed improved survival in patients with LS-SCLC. Results have been hailed as significant advancements in lung cancer treatment, with the potential to change standard care practices. AstraZeneca plans to work with regulators to make these drugs available to patients quickly. Both drugs have shown strong revenue growth for the company in recent years.
Source link
At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer
